These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38447468)

  • 1. Navigating the path of progress: The OMERACT 2023 emerging leaders program.
    Campbell TM; Finzel S; Siddle H; Christensen R; Nielsen SM; Najm A; Otobo TM; Sahbudin I; Sinnathurai P; Stok KS; Touma Z; April KT; Grosskleg S; Tugwell P; Richards B
    Semin Arthritis Rheum; 2024 Jun; 66():152414. PubMed ID: 38447468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future.
    Flurey CA; Tugwell PS; Black RJ; Halls S; Page MJ; Robson JC; Sahbudin I; Siddle HJ; Sinnathurai P; Stok KS; Richards B
    J Rheumatol; 2019 Aug; 46(8):1047-1052. PubMed ID: 30824659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows.
    Chapman LS; Kelly A; Balay-Dustrude E; Bekker C; Berthelsen DB; Ghosh N; Gordon RA; Haas R; Jones C; Luquini A; Weinbrecht-Mischkewitz M; Pickles T; Saygin D; Nielsen W; Webers C; Grosskleg S; Tugwell P; D'Agostino MA; Guillemin F; March L
    Semin Arthritis Rheum; 2024 Apr; 65():152391. PubMed ID: 38340612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.
    Tunis SR; Maxwell LJ; Graham ID; Shea BJ; Beaton DE; Bingham CO; Brooks P; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2017 Oct; 44(10):1551-1559. PubMed ID: 28765256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
    Toupin-April K; Décary S; de Wit M; Meara A; Barton JL; Fraenkel L; Li LC; Brooks P; Shea B; Stacey D; Légaré F; Lydiatt A; Hofstetter C; Proulx L; Christensen R; Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Guillemin F; Beaton D; El-Miedany Y; Mittoo S; Westrich Robertson T; Bartlett SJ; Singh JA; Mannion M; Nasef SI; de Souza S; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Carrott D; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Umaefulam V; Monti S; Melburn C; Abaza N; Schultz K; Stones S; Kiwalkar S; Srinivasalu H; Constien D; King LK; Tugwell P
    Semin Arthritis Rheum; 2021 Jun; 51(3):593-600. PubMed ID: 33892937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.
    Maxwell LJ; Beaton DE; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit M; Gossec L; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1014-1020. PubMed ID: 30770502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.
    Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2.
    Maxwell LJ; Beaton DE; Boers M; D'Agostino MA; Conaghan PG; Grosskleg S; Shea BJ; Bingham Iii CO; Boonen A; Christensen R; Choy E; Doria AS; Hill CL; Hofstetter C; Kroon FP; Leung YY; Mackie S; Meara A; Touma Z; Tugwell P; Wells GA
    Semin Arthritis Rheum; 2021 Dec; 51(6):1320-1330. PubMed ID: 34544617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.
    Kelly A; Tong A; Tymms K; March L; Craig JC; De Vera M; Evans V; Hassett G; Toupin-April K; van den Bemt B; Teixeira-Pinto A; Alten R; Bartlett SJ; Campbell W; Dawson T; Gill M; Hebing R; Meara A; Nieuwlaat R; Shaw Y; Singh JA; Suarez-Almazor M; Sumpton D; Wong P; Christensen R; Beaton D; de Wit M; Tugwell P;
    Trials; 2018 Mar; 19(1):204. PubMed ID: 29587864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.
    Tieu J; Cheah JT; Black RJ; Christensen R; Ghosh N; Richards P; Robson J; Shea B; Simon LS; Singhi JA; Tugwell P; Boers M; Garibay MAA; Campochiaro C; Decary S; de Witt M; Fernandez AP; Keen HI; King L; Hinojosa-Azaola A; Hofstetter C; Gaydukova I; George MD; Gupta L; Lyne S; Makol A; Mukhtyar C; Oo WM; Petri M; Pisaniello HL; Sattui SE; Russell O; Teixeira V; Toupin-April K; Uhunmwangho C; Whitstock M; Yip K; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2021 Oct; 51(5):1139-1145. PubMed ID: 34253398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to promote implementation of core outcomes for medication adherence trials in rheumatology: A report from the OMERACT-Adherence Group.
    Kordkheili AM; Bekker C; Hoens AM; Voshaar M; Campbell W; Carmona L; de Wit M; March L; Nielsen SM; Shea BJ; Toupin-April K; Tugwell P; Tymms K; Kelly A;
    Semin Arthritis Rheum; 2024 Jun; 66():152411. PubMed ID: 38537323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders.
    Ramiro S; Page MJ; Whittle SL; Huang H; Verhagen AP; Beaton DE; Richards P; Voshaar M; Shea B; van der Windt DA; Kopkow C; Lenza M; Jain NB; Richards B; Hill C; Gill TK; Koes B; Foster NE; Conaghan PG; Smith T; Malliaras P; Roe Y; Gagnier JJ; Buchbinder R
    J Rheumatol; 2019 Aug; 46(8):969-975. PubMed ID: 30709947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.
    Orbai AM; Holland R; Leung YY; Tillett W; Goel N; Christensen R; McHugh N; Gossec L; de Wit M; Højgaard P; Coates LC; Mease PJ; Birt J; Fallon L; FitzGerald O; Ogdie A; Shea B; Strand V; Duffin KC; Tugwell P; Beaton D; Gladman DD
    J Rheumatol; 2019 Aug; 46(8):990-995. PubMed ID: 30554154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Joy Factor: Redefining Leadership Excellence at Black in Marine Science through Joy-Centered Leadership Practices.
    Adams L; Moore T
    Integr Comp Biol; 2024 Oct; 64(4):1162-1170. PubMed ID: 39210502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using an employee resource group to develop GRIT in female healthcare leaders: a case study.
    Seegmiller Renner AM; Borgwardt HL; Coyle M; Moeschler S; Bhagra A
    Leadersh Health Serv (Bradf Engl); 2022 Jan; ahead-of-print(ahead-of-print):. PubMed ID: 34978393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets.
    Idzerda L; Rader T; Tugwell P; Boers M
    J Rheumatol; 2014 May; 41(5):986-93. PubMed ID: 24584917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development.
    Humphrey-Murto S; Crew R; Shea B; Bartlett SJ; March L; Tugwell P; Maxwell LJ; Beaton D; Grosskleg S; de Wit M
    J Rheumatol; 2019 Aug; 46(8):1041-1046. PubMed ID: 30770512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.